Alzheimer's Disease Research Guide: Animal Models for Understanding Mechanisms and Medications provides researchers with a comprehensive guide, detailing every aspect of Alzheimer's Disease research, including chapters on neuroinflammation, immunotherapy, biomarkers, and animal modeling. This book begins with historical perspectives of both pathological chronology and pathological biochemistry in relation to Alzheimer’s disease. Other chapters review Amyloidogenic AB and Non-Amyloidogenic tau and Metabolism of AB major components to the research and understanding of Alzheimer’s research. The book concludes with specific treatment chapters including how to develop safe, effective, and inexpensive medications and the application of genome editing to the treatment of Familial Alzheimer's Disease.
Written by world renowned expert in Alzheimer’s research, this book is a valuable resource for all researchers.
1. Chapter 1. Introduction: Collaboration and competition together to maximize the velocity of research and development - p. 1 2. Chapter 2. Pathological chronology and pathological biochemistry: The beginning of the beginning - p. 9 3. Chapter 3. Human genetics: Establishment of cause-and-effect relationships - p. 22 4. Chapter 4. Two major culprits: Amyloidogenic Aβ and non-amyloidogenic tau - p. 47 5. Exact relationship between Aβ40 and Aβ42: An overlooked discovery by Jungsu Kim and colleagues - p. 61 6. Chapter 6. Metabolism of Aβ: Catabolic and glymphatic systems - p. 67 7. Chapter 7. Biology of time: The temporal distance between cause and effect - p. 81 8. Chapter 8. First-generation animal models of Aβ amyoloidosis: Pros and cons of the overexpression paradigm - p. 87 9. Creation of single App knock-in mouse models and of single MAPT knock-in models: Demonstration of Aβ-tau axis - p. 105 10. Applications of App and MAPT knock-in mice to understanding disease mechanisms - p. 137 11. Chapter 11. Neuroinflammation: Microgliosis and astrocytosis in the days of microscopic omics - p. 159 12. Chapter 12. Central and peripheral nervous system, immune systems and digestive system: AD as a systemic disorder - p. 169 13. Chapter 13. Failure of more than 400 candidate medications in clinical trials before 2020 - p. 177 14. Chapter 14. Therapeutic antibodies as a Wright Brothers' airplane: Clinical proof-of-concept - p. 185 15. Chapter 15. Biomarkers for presymptomatic diagnosis and prognosis - p. 197 16. Chapter 16. Targeting somatostatin receptor heterodimer for effective and economically viable medications without side effects - p. 209 17. Chapter 17. Application of genome editing to the treatment of familial AD - p. 217 18. Chapter 18. Identifying significant and insignificant publications: Prelude for Chapter 19 - p. 227 19. Chapter 19. Journal of Negative Data for the days of generative AI-assisted publication - p. 235 20. Chapter 20. Conclusions: Let's make the world ADless! - p. 237 21. Eulogy to the late Yasuo Ihara - p. 243 22. Postscript - p. 247 23. Index - p. 253
Alzheimer's Disease Research Guide: Animal Models for Understanding Mechanisms and Medications provides researchers with a comprehensive guide, detailing every aspect of Alzheimer's Disease research, including chapters on neuroinflammation, immunotherapy, biomarkers, and animal modeling. This book begins with historical perspectives of both pathological chronology and pathological biochemistry in relation to Alzheimer’s disease. Other chapters review Amyloidogenic AB and Non-Amyloidogenic tau and Metabolism of AB major components to the research and understanding of Alzheimer’s research. The book concludes with specific treatment chapters including how to develop safe, effective, and inexpensive medications and the application of genome editing to the treatment of Familial Alzheimer's Disease.
Written by world renowned expert in Alzheimer’s research, this book is a valuable resource for all researchers.
1. Chapter 1. Introduction: Collaboration and competition together to maximize the velocity of research and development - p. 1 2. Chapter 2. Pathological chronology and pathological biochemistry: The beginning of the beginning - p. 9 3. Chapter 3. Human genetics: Establishment of cause-and-effect relationships - p. 22 4. Chapter 4. Two major culprits: Amyloidogenic Aβ and non-amyloidogenic tau - p. 47 5. Exact relationship between Aβ40 and Aβ42: An overlooked discovery by Jungsu Kim and colleagues - p. 61 6. Chapter 6. Metabolism of Aβ: Catabolic and glymphatic systems - p. 67 7. Chapter 7. Biology of time: The temporal distance between cause and effect - p. 81 8. Chapter 8. First-generation animal models of Aβ amyoloidosis: Pros and cons of the overexpression paradigm - p. 87 9. Creation of single App knock-in mouse models and of single MAPT knock-in models: Demonstration of Aβ-tau axis - p. 105 10. Applications of App and MAPT knock-in mice to understanding disease mechanisms - p. 137 11. Chapter 11. Neuroinflammation: Microgliosis and astrocytosis in the days of microscopic omics - p. 159 12. Chapter 12. Central and peripheral nervous system, immune systems and digestive system: AD as a systemic disorder - p. 169 13. Chapter 13. Failure of more than 400 candidate medications in clinical trials before 2020 - p. 177 14. Chapter 14. Therapeutic antibodies as a Wright Brothers' airplane: Clinical proof-of-concept - p. 185 15. Chapter 15. Biomarkers for presymptomatic diagnosis and prognosis - p. 197 16. Chapter 16. Targeting somatostatin receptor heterodimer for effective and economically viable medications without side effects - p. 209 17. Chapter 17. Application of genome editing to the treatment of familial AD - p. 217 18. Chapter 18. Identifying significant and insignificant publications: Prelude for Chapter 19 - p. 227 19. Chapter 19. Journal of Negative Data for the days of generative AI-assisted publication - p. 235 20. Chapter 20. Conclusions: Let's make the world ADless! - p. 237 21. Eulogy to the late Yasuo Ihara - p. 243 22. Postscript - p. 247 23. Index - p. 253
